Adage Capital Partners
LAB icon

Adage Capital Partners’s Standard BioTools LAB Stock Holding History

Adage Capital Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-400,000
Closed -$2.64M – 1067
2021
Q3 		$2.64M Buy
+400,000
New +$2.63M 0.01% 877
2018
Q2 		– Sell
-18,726
Closed -$109K – 768
2018
Q1 		$109K Sell
18,726
-1,165,407
-98% -$7.65M ﹤0.01% 713
2017
Q4 		$6.97M Sell
1,184,133
-647,119
-35% -$3.54M 0.02% 604
2017
Q3 		$9.23M Sell
1,831,252
-114,957
-6% -$483K 0.02% 569
2017
Q2 		$7.86M Buy
1,946,209
+400,000
+26% +$1.9M 0.02% 598
2017
Q1 		$8.8M Buy
1,546,209
+667,129
+76% +$4.23M 0.02% 558
2016
Q4 		$6.4M Buy
879,080
+278,880
+46% +$1.75M 0.02% 586
2016
Q3 		$4.81M Buy
+600,200
New +$5.51M 0.01% 615
2015
Q3 		– Sell
-200,000
Closed -$4.84M – 739
2015
Q2 		$4.84M Buy
+200,000
New +$6.31M 0.01% 641
2014
Q3 		– Sell
-50,000
Closed -$1.47M – 735
2014
Q2 		$1.47M Buy
+50,000
New +$1.6M ﹤0.01% 663

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners's LAB Position: Q4 2021 in Review

Adage Capital Partners sold out of Standard BioTools (LAB) in Q4 2021, closing a stake of 400,000 shares — an estimated $2.64M sold.

Adage Capital Partners first reported a position in LAB in Q2 2014 and held it in 10 quarters. The position peaked at $9.23M in Q3 2017. 121 funds tracked by Wall St. Rank hold LAB as of Q4 2021.

  • Adage Capital Partners reported no remaining Standard BioTools position as of Q4 2021 after selling out during the quarter.
  • Adage Capital Partners sold 400,000 Standard BioTools shares in Q4 2021, an estimated $2.64M.
  • Adage Capital Partners first reported a position in Standard BioTools in Q2 2014 and held it in 10 quarters.
  • Adage Capital Partners's Standard BioTools position peaked at $9.23M in Q3 2017.
  • 121 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2021.

Based on Adage Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.